GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xlife Sciences AG (XSWX:XLS) » Definitions » Debt-to-EBITDA

Xlife Sciences AG (XSWX:XLS) Debt-to-EBITDA : 1.19 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Xlife Sciences AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Xlife Sciences AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.95 Mil. Xlife Sciences AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF55.57 Mil. Xlife Sciences AG's annualized EBITDA for the quarter that ended in Dec. 2023 was CHF47.37 Mil. Xlife Sciences AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.19.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Xlife Sciences AG's Debt-to-EBITDA or its related term are showing as below:

XSWX:XLS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.17   Med: 2.7   Max: 34.48
Current: 2.7

During the past 6 years, the highest Debt-to-EBITDA Ratio of Xlife Sciences AG was 34.48. The lowest was 1.17. And the median was 2.70.

XSWX:XLS's Debt-to-EBITDA is ranked worse than
64.49% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs XSWX:XLS: 2.70

Xlife Sciences AG Debt-to-EBITDA Historical Data

The historical data trend for Xlife Sciences AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xlife Sciences AG Debt-to-EBITDA Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 34.48 2.44 1.17 2.91 2.70

Xlife Sciences AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 -7.49 1.22 -10.16 1.19

Competitive Comparison of Xlife Sciences AG's Debt-to-EBITDA

For the Biotechnology subindustry, Xlife Sciences AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Debt-to-EBITDA falls into.



Xlife Sciences AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Xlife Sciences AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.951 + 55.573) / 20.949
=2.70

Xlife Sciences AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.951 + 55.573) / 47.366
=1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Xlife Sciences AG  (XSWX:XLS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Xlife Sciences AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Xlife Sciences AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Xlife Sciences AG (XSWX:XLS) Business Description

Traded in Other Exchanges
Address
Talacker 35, Zürich, CHE, 8001
Xlife Sciences AG is a Swiss company with a focus on performance technologies in life sciences. The company allows its investors a very early and direct Entry into the further development of innovative and future-oriented technologies.

Xlife Sciences AG (XSWX:XLS) Headlines

No Headlines